CARMAT Announces the Approval of All Resolutions Supported by the Board of Directors at Its Annual General Meeting

PARIS, May 30, 2024--(BUSINESS WIRE)--Regulatory News:

CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the "Company" or "CARMAT"), informs its shareholders that the Combined General Meeting (AGM) held on May 30, 2024, was able to validly deliberate, the required quorum having been reached.

The AGM adopted all proposed resolutions, with the exception of the 28^th resolution which was rejected, in accordance with the recommendations of the Board of Directors.

The Company would like to thank all shareholders, either present, represented or having voted by post, for their commitment and support.

The consolidated result of the vote by resolution and the minutes of the AGM of May 30, 2024 will be available on the Company's website, under Regulated Information / General Meetings, within the legal deadlines.

About CARMAT

CARMAT is a French MedTech that designs, manufactures and markets the Aeson^® artificial heart. The Company’s ambition is to make Aeson^® the first alternative to a heart transplant, and thus provide a therapeutic solution to people suffering from end-stage biventricular heart failure, who are facing a well-known shortfall in available human grafts. The world’s first physiological artificial heart that is highly hemocompatible, pulsatile and self-regulated, Aeson^® could save, every year, the lives of thousands of patients waiting for a heart transplant. The device offers patients quality of life and mobility thanks to its ergonomic and portable external power supply system that is continuously connected to the implanted prosthesis. Aeson^® is commercially available as a bridge to transplant in the European Union and other countries that recognize CE marking. Aeson^® is also currently being assessed within the framework of an Early Feasibility Study (EFS) in the United States. Founded in 2008, CARMAT is based in the Paris region, with its head offices located in Vélizy-Villacoublay and its production site in Bois-d’Arcy. The Company can rely on the talent and expertise of a multidisciplinary team of circa 200 highly specialized people. CARMAT is listed on the Euronext Growth market in Paris (Ticker: ALCAR / ISIN code: FR0010907956).

For more information, please go to www.carmatsa.com and follow us on LinkedIn.

Name: CARMAT
ISIN code: FR0010907956
Ticker: ALCAR

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, nor a solicitation of an order to buy or subscribe to CARMAT shares in any country. This press release may contain forward-looking statements by the company regarding its objectives and prospects. These forward-looking statements are based on the current estimates and anticipations of the company's management and are subject to risk factors and uncertainties such as the company's ability to implement its strategy, the pace of development of CARMAT's production and sales, the pace and results of ongoing or planned clinical trials, technological evolution and competitive environment, regulatory changes, industrial risks, and all risks associated with the company's growth management. The company's objectives mentioned in this press release may not be achieved due to these elements or other risk factors and uncertainties.

The Company's material and specific risks are those described in its universal registration document filed with the Autorité des Marchés Financiers (AMF) under number D.24-0374. Readers' attention is particularly drawn to the fact that the Company's current financing horizon is limited to mid-August 2024. Readers' and investors' attention is also drawn to the fact that other risks, unknown or not considered material and specific, may or may not exist.

Aeson^® is an active implantable medical device commercially available in the European Union and other countries recognizing CE marking. The Aeson^® total artificial heart is intended to replace the ventricles of the native heart and is indicated as a bridge to transplant for patients suffering from end-stage biventricular heart failure (INTERMACS classes 1-4) who cannot benefit from maximal medical therapy or a left ventricular assist device (LVAD) and who are likely to undergo a heart transplant within 180 days of implantation. The decision to implant and the surgical procedure must be carried out by healthcare professionals trained by the manufacturer. The documentation (clinician manual, patient manual, and alarm booklet) should be carefully read to understand the features of Aeson^® and the information necessary for patient selection and proper use (contraindications, precautions, side effects). In the United States, Aeson^® is currently exclusively available as part of an Early Feasibility Study approved by the Food & Drug Administration (FDA).

View source version on businesswire.com: https://www.businesswire.com/news/home/20240530997748/en/

Contacts

CARMAT
Stéphane Piat
Chief Executive Officer

Pascale d’Arbonneau
Chief Financial Officer
Tel.: +33 1 39 45 64 50
contact@carmatsas.com

Alize RP
Press Relations

Caroline Carmagnol
Tel.: +33 6 64 18 99 59
carmat@alizerp.com

NewCap
Financial Communication
& Investor Relations

Dusan Oresansky
Jérémy Digel
Tel.: +33 1 44 71 94 92
carmat@newcap.eu